73406-97-0

Basic information

• Product Name: 5-BROMO-2-(PIPERAZIN-1-YL)PYRIDINE
• Synonyms: 1-(5-BROMO-PYRIDIN-2-YL)-PIPERAZINE;5-BROMO-2-(PIPERAZIN-1-YL)PYRIDINE;1-(5-Bromo-2-pyridinyl)piperazine;Piperazine, 1-(5-bromo-2-pyridinyl);1-(5-BroMo-pyridin-2-yl)-piperazine hydrochloride
• CAS NO: 73406-97-0
• Molecular Formula: C₉H₁₂BrN₃
• Molecular Weight: 242.12
• Product Categories: pharmacetical;API intermediates;Organohalides;Pyridine
• Mol File: 73406-97-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 366.687 °C at 760 mmHg
• Flash Point: 175.567 °C
• Appearance: /
• Density: 1.449g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.58
• CAS DataBase Reference: 5-BROMO-2-(PIPERAZIN-1-YL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-(PIPERAZIN-1-YL)PYRIDINE(73406-97-0)
• EPA Substance Registry System: 5-BROMO-2-(PIPERAZIN-1-YL)PYRIDINE(73406-97-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• Hazardous Substances Data: 73406-97-0(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-(piperazin-1-yl)pyridine is a chemical compound with the molecular formula C9H11BrN4. It is a brominated pyridine derivative that contains a piperazine ring. 5-BROMO-2-(PIPERAZIN-1-YL)PYRIDINE is frequently used in pharmaceutical research as a building block for the synthesis of various biologically active compounds. It is also used as a reagent in the development of new drugs and as a precursor in the production of agrochemicals. The presence of the piperazine ring makes this compound potentially useful as a ligand in coordination chemistry and in the synthesis of organometallic complexes. Additionally, the bromine substituent can impart unique reactivity and properties to the molecule, making it valuable for medicinal and chemical research.

InChI:InChI=1/C9H12BrN3/c10-8-1-2-9(12-7-8)13-5-3-11-4-6-13/h1-2,7,11H,3-6H2

Upstream product

• 110-85-0 piperazine 
• 624-28-2 2,5-dibromopyridine 
• 7693-46-1 4-Nitrophenyl chloroformate 
• 53939-30-3 5-bromo-2-chloropyridine 
• 766-11-0 5-bromo-2-fluoropyridine 
• 153747-97-8 5-Bromo-2-(4-tert-butoxycarbonylpiperazin-1-yl)pyridine 
• 60-29-7 diethyl ether 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1359087-65-2 C₁₉H₂₃BrN₄O₄S 
• 1215010-54-0 2,6-dichloro-4-(6-(piperazin-1-yl)pyridin-3-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide 
• 494771-76-5 1-[4-(5-bromopyridin-2-yl)piperazin-1-yl]ethanone 
• 823197-35-9 1-[5-(benzyloxy)pyridin-2-yl]piperazine 
• 153747-97-8 5-Bromo-2-(4-tert-butoxycarbonylpiperazin-1-yl)pyridine 
• 496786-98-2 2-(4-tert-butyloxycarbonyl-piperizin-1-yl)pyridine-5-boronic acid pinacol ester 

Relevant articles and documents

PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF

Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.

Substituted pyridine compound and its method and use thereof

The invention relates to a novel substitutive pyridine compound, and a pharmaceutically acceptable salt and a pharmaceutical preparation of the substitutive pyridine compound for regulating the activity of protein kinases and regulating signal responses between cells or in the cells. Meanwhile, the invention further relates to a pharmaceutical composition containing the compound provided by the invention, and a method for treating high proliferative diseases of mammals, especially human with the pharmaceutical composition.

GLYCINE COMPOUND

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.